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Abstract
Background: Extracts of the creosote bush, Larrea tridentata, have been used for centuries by
natives of western American and Mexican deserts to treat a variety of infectious diseases and
inflammatory disorders. The beneficial activity of this plant has been linked to the compound
nordihydroguaiaretic acid (NDGA) and its various substituted derivatives. Recently, tetra-O-
methyl NDGA or terameprocol (TMP) has been shown to inhibit the growth of certain tumor-
derived cell lines and is now in clinical trials for the treatment of human cancer. In this report, we
ask whether TMP also displays anti-inflammatory activity. TMP was tested for its ability to inhibit
the LPS-induced production of inflammatory lipids and cytokines in vitro. We also examined the
effects of TMP on production of TNF-α in C57BL6/J mice following a sublethal challenge with LPS.
Finally, we examined the molecular mechanisms underlying the effects we observed.
Methods: RAW 264.7 cells and resident peritoneal macrophages from C57BL6/J mice, stimulated
with 1 μg/ml LPS, were used in experiments designed to measure the effects of TMP on the
production of prostaglandins, cytokines and chemokines. Prostaglandin production was determined
by ELISA. Cytokine and chemokine production were determined by antibody array and ELISA.
Western blots, q-RT-PCR, and enzyme assays were used to assess the effects of TMP on
expression and activity of COX-2.
q-RT-PCR was used to assess the effects of TMP on levels of cytokine and chemokine mRNA.
C57BL6/J mice injected i.p. with LPS were used in experiments designed to measure the effects of
TMP in vivo. Serum levels of TNF-α were determined by ELISA.
Results: TMP strongly inhibited the production of prostaglandins from RAW 264.7 cells and
normal peritoneal macrophages. This effect correlated with a TMP-dependent reduction in levels
of COX-2 mRNA and protein, and inhibition of the enzymatic activity of COX-2.
TMP inhibited, to varying degrees, the production of several cytokines, and chemokines from RAW
264.7 macrophages and normal peritoneal macrophages. Affected molecules included TNF-α and
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MCP-1. Levels of cytokine mRNA were affected similarly, suggesting that TMP is acting to prevent
gene expression.
TMP partially blocked the production of TNF-α and MCP-1 in vivo in the serum of C57BL6/J mice
that were challenged i.p. with LPS.
Conclusion:  TMP inhibited the LPS-induced production of lipid mediators and several key
inflammatory cytokines and chemokines, both in vitro and in vivo, raising the possibility that TMP
might be useful as a treatment for a variety of inflammatory disorders.
Background
The creosote bush, Larrea tridentata, is common in the
Sonoran deserts of Mexico and the American southwest.
The Pima, Yaqui, Maricopa and Seri tribes have used vari-
ous extracts and preparations from this plant to treat a
wide variety of disorders [1,2]. The leaves can be used in a
bath for chicken pox or rheumatism, while a decoction
made from the boiled leaves is used as a poultice for skin
sores. Skin sores can also be treated with a powder made
from dried leaves and stems. The leaves can be used to
make a tea (chaparral tea) that is used to treat many disor-
ders including cancer, venereal disease, tuberculosis,
colds, and rheumatism. Consumption of high levels of L.
tridentata can cause hepatic necrosis [3,4], although dam-
age is temporary and reversed when L. tridentata is with-
drawn from the diet.
The leaves and stems of L. tridentata contain high quanti-
ties of the phenolic compound nordihydroguaiaretic acid
(NDGA), a lipophilic anti-oxidant that has been used as a
preservative in fats and oils. Many of the medicinal effects
of L. tridentata have also been attributed to the effects of
this compound [2]. NDGA has been shown to inhibit 5-
lipoxygenase activity in vitro [5,6], and experiments have
shown that it inhibits neutrophil production of LTB4
[7,8], degranulation [7,8], phagocytosis [9], and the respi-
ratory burst [9]. NDGA affects levels of intracellular cal-
cium [10,11], as well as exerting effects on mitochondria
[12,13], and the Golgi complex [14-16]. NDGA has been
shown to exert anti-tumor effects [17] and to block apop-
tosis induced either by tumor necrosis factor-α (TNF) [18-
21] or CD95 ligand [22,23].
L. tridentata leaves also contain 3-O-methyl NDGA, with
one methyoxl and three hydroxyl side chains rather than
the four hydroxyl groups found on NDGA [24]. 3-O-
methyl NDGA has been shown to inhibit replication of a
number of strains of HIV and prevent both basal tran-
scription and Tat-regulated transactivation in vitro [24].
This effect arises from the ability of 3-O-methyl NDGA to
interfere with the binding of the transcription factor Sp1
to the long terminal repeats of HIV, an effect that was not
seen with NDGA itself [24]. Based on these results, eight
distinct methylated forms of NDGA were tested for their
effects on HIV Tat-mediated transactivation [25]. The
results of this investigation revealed that tetra-O-methyl
NDGA (also known as M4N or terameprocol (TMP)) dis-
played the highest level of anti-HIV activity [25]. TMP has
also been shown to block the replication of herpes sim-
plex virus in vitro [26] and to inhibit transcription from
the early promoter P97 of human papillomavirus 16 in
transfected cells [27]. Both effects were again attributed to
the ability of TMP to interfere with the binding of Sp1 to
DNA. TMP has been found to arrest the growth of certain
tumor-derived cell lines in the G2 phase of the cell cycle by
inhibiting production of cyclin-dependent kinase cdc2
mRNA [28]. Experiments in vivo with mice, with a number
of different tumor-derived and transformed cell lines,
revealed a similar growth inhibitory effect resulting from
decreased gene expression of both cdc2 and survivin
[28,29] leading to the suggestion that TMP may be useful
in humans to treat cancer. Indeed, three clinical trials with
TMP to treat human tumors have been completed and two
more are now underway (Clinicaltrials.gov database,
accessed 5/28/08).
In this report we have investigated a novel role for TMP; as
an inhibitor of inflammation. We reasoned that TMP
might have anti-inflammatory activity since many of the
disorders for which L. tridentata is traditionally used con-
tain an inflammatory component. In this manuscript we
have focused on TMP's ability to inhibit production of
inflammatory lipids and cytokines from macrophages and
macrophage-like cells. The results of our experiments
reveal inhibition of both cytokine and lipid mediator pro-
duction and suggest that multiple molecular mechanisms
underlie these effects. Overall, our data suggest that TMP




RAW 264.7 cells were obtained from the American Type
Culture Collection (Manassas, VA) and were cultured in
Dulbecco's Modified Eagle's (DME) Medium with 4 mM
L-glutamine, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate
with 10% FCS. Most media and supplements were
obtained from Sigma-Aldrich, St. Louis, MO. FCS wasJournal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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obtained from Atlanta Biologicals, Atlanta, GA. For pro-
duction of cell culture supernatants, 1.5 × 105 cells/well
were plated in 24 well tissue culture plates in 1 ml culture
media. Following treatment, supernatants were collected,
centrifuged for 2 min at 8,000 rpm to remove debris, aliq-
uoted and stored at -80°C. Normal resident peritoneal
macrophages were obtained from 8–10 week old
C57BL6/J mice (Charles River Laboratories, Inc. Wilming-
ton, MA). Peritoneal lavage was performed with DME
serum-free media. Following washing, the resulting cells
were plated in DME with 10% FCS, incubated overnight,
and then washed to remove non-adherent cells.
Chemicals and Biological Reagents
Unless otherwise indicated, reagents were purchased from
Sigma-Aldrich, St. Louis, MO. TMP was supplied by Eri-
mos Pharmaceuticals, Raleigh, NC. DMSO was used as the
solvent for TMP in all experiments except for those per-
formed in vivo with mice. The maximum DMSO concen-
tration was 1.0% in all assays. This concentration of
DMSO was tested in all assays and did not affect the
results. LPS from Salmonella  Minnesota R595 was pur-
chased from LIST Biological Laboratories, Inc. (Campbell,
CA).
ELISA kits
PGE2, 6-keto-PGF1α, MCP-1, IL-12/23 p40, RANTES, and
TNF-α ELISA kits were purchased from R&D Systems
(Minneapolis MN), Assay Designs (Ann Arbor, MI), eBio-
science (San Diego, CA), or USBiological (Swampscott,
MA). The PGF2α kit was purchased from Assay Designs
and the IL-23p19 kit was purchased from eBioscience. All
lipid mediator kits are competitive type immunoassays
while the cytokine kits are direct capture assays. In each
case, sample values were interpolated from standard
curves. Optical density was determined using a PolarStar
microplate reader (BMG Labtechnologies, Durham, NC).
Cytokine arrays
For cytokine analysis, the RayBio Mouse Inflammation
Antibody Array I was purchased from RayBiotech, Inc.,
Norcross, GA. According to manufacturer's instructions,
the array membranes were incubated with blocking buffer
followed by undiluted culture supernatants for 1.5 h.
Then, the membranes were washed, incubated with
biotin-conjugated Abs for 1.5 h and HRP-conjugated
strepavidin for 2 h. The membranes were next incubated
in detection buffer and exposed to X-ray film. Finally,
scans of the X-ray films were analyzed with Photoshop
(Adobe) to determine spot density.
Intraperitoneal challenge with LPS
Animal experiments were carried out in accord with
approved IACUC protocol. Each group of experimental
animals consisted of 5, 6–8 week old, 15–16 g C57BL6/J
mice (Charles River). The groups received i.p. injections of
either PBS, hydroxypropyl-β-cyclodextrin with PEG 300
(CPE) vehicle [30], 20 μg of LPS in CPE vehicle, 1 mg of
TMP in CPE vehicle, or 20 μg of LPS and 1 mg TMP in
vehicle. CPE vehicle and TMP/CPE vehicle injections were
administered 1 h prior to LPS or PBS injections. Injection
volumes were 100 μl for TMP and vehicle and 200 μl for
LPS and PBS. The mice were monitored for 3 hours, sacri-
ficed, and blood collected by cardiac puncture. Serum was
separated and levels of TNF-α, PGE2, and MCP-1 deter-
mined by ELISA.
Collection of peritoneal macrophages
Macrophages were collected by peritoneal lavage from 6–
8 week old C57BL6/J mice (Charles River).
After collection the cells were centrifuged, counted and
plated at 2 × 105 per well in 24 well tissue culture plates.
The cells were allowed to adhere for 2–4 hr, washed to
remove non-adherent cells and then treated as described
within 24 h.
Quantitative RT-PCR assays
Total RNA of treated and untreated cells was extracted
using the RNAeasy kit (Qiagen, Valencia, CA) according to
manufacturer's specifications. Residual genomic DNA was
eliminated by using on-column DNase digestion with the
RNase-free DNase set (Qiagen) and resulting extracts were
resuspended in nuclease free water. Total amount and
purity of RNA was determined using a Nanodrop 1000
spectrophotometer (ThermoFisher Scientific, Waltham,
MA). Total RNA (1 μg) was denatured and reverse tran-
scription was performed with the Improm ll reverse tran-
scription kit (Promega, Madison, WI) in a reaction mix
containing random hexamers as primers (50 ng/μl) for 60
min at 42°C. The iQTM SYBR Green supermix kit (Bio-
Rad, Hercules, CA), was used for Real-time PCR analysis,
cDNA was amplified using primers specific for murine
GAPDH, TNF-α, MCP-1, RANTES and COX-2. Primer
combinations are GAPDH [antisense: 5' ATG TCA GAT
CCA CAA CGG ATA GAT 3'; sense: 5' ACT CCC TCA AGA
TTG TCA GCA AT 3']; TNF-α [antisense: 5' AGA AGA GGC
ACT CCC CCA AAA 3'; sense: 5' CCG AAG TTC AGT AGA
CAG AAG AGC G 3']; MCP-1 [sense: 5' CAC TAT GCA
GGT CTC TGT CAC G 3'; antisense: 5' GAT CTC ACT TGG
TTC TGG TCC A 3']; RANTES: [sense: 5' CCC CAT ATG
GCT CGG ACA CCA 3'; antisense: 5' CTA GCT CAT CTC
CAA ATA GTT GAT 3']; COX-2: [sense: 5' GCA TTC TTT
GCC CAG CAC TT 3'; antisense: 5' AGA CCA GGC ACC
AGA CCA AAG A 3']. All primer pairs were purchased
from Integrated DNA Technologies, Coralville, IA.
Cycling conditions for all PCRs are available upon
request.
PCR was performed in 96 well plates (Eppendorf AG,
Hamburg, Germany). Samples were amplified for a total
of 50 cycles, followed by a meltcurve analysis to ensureJournal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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the specificity of reactions. To generate a standard curve,
total RNA was isolated from the cells and 300–600 bp
fragments of the gene of interest were amplified by RT-
PCR using cognate primer sets. PCR fragments were gel
purified, quantified and the copy number was calculated.
Serial ten fold dilutions were prepared for use as templates
to generate standard curves. All samples were normalized
to amplified murine GAPDH. GAPDH control was ana-
lyzed per plate of experimental genes to avoid plate-to-
plate variation. Final RT-PCR data is expressed as the ratio
of copy numbers of experimental gene per 103 copies of
GAPDH for samples performed in duplicates.
Peroxidase Assay for the measurement of COX-2 Activity
Inhibition of the peroxidase activity of purified COX-2
enzyme was measured using a modified chromogenic
assay, described previously [31], in which N,N,N',N'-
tetramethyl-p-phenylenediamine (TMPD) was utilized to
measure the oxidation of PGG2 to PGH2. Briefly, approxi-
mately 100 U/ml of ovine COX-2 (Cayman Chemical Co.,
Ann Arbor, MI) was mixed with an assay buffer containing
100 mM Tris-HCl pH 8.0, 1 μM bovine hemin and the
inhibitor TMP. This mixture was incubated in a tempera-
ture controlled 1 cm glass cuvette at 25°C for 10 minutes
to allow for enzyme and inhibitor equilibration. The per-
oxidase activity of the COX-2 enzyme was initiated by
adding 100 μM arachidonic acid. TMPD (170 μM final)
was added at the same time as the arachidonic acid and
the reaction was monitored for six minutes using a Shi-
madzu UV-2401PC kinetic reading spectrophotometer
(Shimadzu, Kyoto, Japan) at 611 nm. Absorbance was
recorded at one second intervals using UV probe software
(Shimadzu). After three minutes hydrogen peroxide was
added to a final concentration of 70 μM to further catalyze
the peroxidase reaction and the kinetic reading was con-
tinued for an additional three minutes. Control reactions
were analyzed without inhibitor or without enzyme for
comparison.
Immunoblotting
Cell monolayers were washed twice with cold phosphate
buffered saline (PBS), solubilized in lysis buffer (50 mM
Hepes, pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.2 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 0.2
mM leupeptin, 0.5% SDS), and collected by scraping. The
protein concentration for each sample lysate was deter-
mined using the Pierce BCA system (Pierce, Rockford, IL).
Equal protein samples (15 to 30 μg) were loaded on 8%
Tris-Glycine gels and subjected to electrophoresis using
the Novex Mini-Cell System (Invitrogen). Following
transfer, blocking and probing, bands were visualized
using the SuperSignal Chemiluminescent system (Pierce,
Rockford, IL). Scans of films were then analyzed with Pho-
toshop (Adobe) to determine band density.
[3H]AA-release assays
2.5 × 104 cells were plated into 24-well flat-bottom tissue
culture plates (Fisher Scientific, Pittsburgh, PA) and
labeled overnight with 0.1 μCi/ml [3H]AA. The following
morning, the cells were washed 2× with Hank's balanced
salt solution (HBSS), allowed to recover for an additional
2 h, and washed again prior to treatment. At indicated
time points, 275 μl aliquots of media were removed from
the wells and centrifuged to remove debris. 200 μl of the
supernatant was removed for scintillation counting (LS
5801, Beckman, Fullerton, CA) and total [3H]AA-release
was calculated by multiplying by a factor of 2. Each point
was performed in triplicate and maximum radiolabel
incorporation was determined by lysing untreated con-
trols with 0.01% SDS and counting the total volume.
Influenza A virus propagation
Influenza A/PR/8/34 (VR-1469) was purchased from the
American Type Culture Collection (Manassas, VI) and
propagated in MDCK Cells (ATCC CCL-34). T-75 flasks of
cells at 90% confluency were inoculated with 0.01 MOI of
virus in 2 ml of Virus Growth Medium (VGM) made up of
DMEM containing 0.2% BSA, 25 mM Hepes buffer, 100
U/ml Penicillin, 100 μg/ml Streptomycin, and 2 μg/ml
TPCK-treated Trypsin (LS003740, Worthington-Biochem,
Lakewood, NJ). Viral supernatants were harvested at 36 to
48 h, centrifuged to remove cellular debris, and supple-
mented with BSA to a final concentration of 0.5%. Aliq-
uots were frozen and stored at -80°C. Titers of influenza
A virus were determined by plaque assay using MDCK
cells. Briefly, 200 μl of serially diluted virus in VGM was
inoculated onto confluent MDCK cells in 24-well plates.
After a 30 min absorption period, 0.8 ml of overlay was
added (0.6% Tragacanth in VGM). After 48 h of incuba-
tion the overlay was removed, the cells washed with cold
PBS, fixed with cold acetone:methanol (1:1), and stained
with crystal violet.
Statistical analyses
Statistical analyses were performed with PRISM® software
(Graphpad Software, San Diego, CA). Significant differ-
ences between means were determined using unpaired
Student's t-tests with 95% confidence intervals.
Assay for cell proliferation
To evaluate the effects of TMP on cell proliferation we uti-
lized the CyQUANT Cell Proliferation Assay Kit (Molecu-
lar Probes, Eugene OR). Briefly, cells were seeded in
triplicate at a density of 5 × 103 cells/well in 96 well plates
and allowed to adhere for 24 h. Treatments were then per-
formed and the plates processed according to manufac-
turer's instructions. The fluorescence intensity of
CyQUANT GR dye, which is proportional to cellular DNA
content, was then measured using the PolarStar micro-
plate reader (BMG Labtechnologies, Durham, NC).Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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Assay for apoptosis
An assay for active caspase-3 (Cayman Chemical Co., Ann
Arbor MI, #10009135) was used to monitor the apopto-
sis-inducing activity of TMP. Briefly, RAW 264.7 cells were
plated in 96 well tissue culture plates and treated with
TMP for 24 h. Then, according to the manufacturer's
instructions, the medium was removed, cells washed and
lysis buffer added. A substrate for active caspase 3 (N-Ac-
DEVD-N-MC-R110) was then added which, when cleaved
by caspase 3, generates a fluorescent product with an
emission maximum of 535 nm. Positive and negative con-
trols were supplied by the manufacturer. All points were
performed in triplicate and values shown are means +/-
SEM.
Results
TMP and prostaglandin production
The goal of this set of experiments was to determine
whether TMP can inhibit production of prostaglandins
from RAW 264.7 macrophage-like cells. These cells have
been used extensively as a model for prostaglandin pro-
duction by primary macrophages [32-34]. As shown in
Fig. 1A, we found that treatment of RAW 264.7 cells with
1 μg/ml of LPS induced robust PGE2 production. PGE2
was first detected 4–6 h after treatment with LPS began,
and levels continued to rise during the remainder of the
treatment period. Fig. 1A also shows that TMP at 25 μM
strongly inhibited production of PGE2. This effect was
apparent early and maintained throughout the 16 h incu-
bation period. As shown in Fig. 1B, we found that TMP
displayed concentration-dependent inhibition of prostag-
landin production. Typically, a 10 μM concentration of
TMP inhibited PGE2 production by approximately 60%
while levels of inhibition reached 80–90% with 25 μM
TMP.
Our experiments showed that the inhibitory effect of TMP
was not selective for production of PGE2. As shown in
Figs. 1C and 1D, 25 μM TMP inhibited the LPS-induced
production of PGF2α and PGI2/prostacylin (as measured
by production of the PGI2  hydration product 6-keto-
PGF1α). In addition, we found that the inhibitory effects
of TMP are not specific for LPS-induced prostaglandin
production. TMP inhibited production of PGE2  when
PMA (Fig. 1E) or the influenza A virus PR/8/34 (Fig. 1F)
were used as agonists. Finally, it should be noted that in
all the experiments shown in Fig. 1, TMP and LPS were
added simultaneously to the RAW 264.7 cells. Several
experiments were performed in which the RAW 264.7
cells were pretreated with TMP (for up to several hours)
but we did not find any enhanced suppression of PGE2
production following treatment with LPS (data not
shown).
TMP and its effects on the expression and activity of COX-2
Our next set of experiments was designed to understand
the molecular mechanism by which TMP inhibited pros-
taglandin production. TMP's ability to inhibit the produc-
tion of different prostaglandins, and to inhibit the
production of PGE2 induced by different agonists, sug-
gested that TMP was likely acting on a common, down-
stream element of the prostaglandin biosynthetic
pathway, such as cytosolic phospholipase A2 (cPLA2) [35]
or COX-2 [36,37]. As shown in Fig. 2A, we found that
TMP failed to inhibit the LPS-induced release of [3H]-ara-
chidonic acid from prelabeled cells. In fact, [3H]-arachi-
donic acid release was actually enhanced by TMP. These
results are consistent with TMP exerting a block in arachi-
donic acid metabolism downstream from cPLA2. There-
fore, a series of experiments was performed to examine
the effects of TMP on the expression and activity of COX-
2. Initially, we examined the effects of TMP on the expres-
sion of COX-2 mRNA. As shown in Fig. 2B, we found that
TMP reduced the LPS-induced expression of COX-2
mRNA, and a deficit of approximately 40% was evident
after a 16 h treatment with LPS. However, the significance
of this finding is unclear. As shown in Fig. 2C, we found
that TMP caused only an approximate 20% reduction in
COX-2 protein expression under the same conditions.
Finally, we also tested whether TMP could directly inhibit
the enzymatic activity of COX-2. An assay was established
in which the activity of purified ovine COX-2, alone or in
the presence of inhibitors, could be measured spectropho-
tometrically. As shown in Fig. 2D, we found that the activ-
ity of COX-2 was inhibited by 40–50% in the presence of
25 μM TMP while inhibition of COX-2 activity was essen-
tially complete in the presence 50 μM TMP. The level of
inhibition of COX-2 activity by 50 μM TMP was compara-
ble to that observed in the presence of 10 μM NS-398, a
well characterized inhibitor of COX-2 [38].
The effects of TMP on cytokine production
Macrophage derived cytokines are critical to a variety of
inflammatory processes and, therefore, we sought to eval-
uate TMP's effect on cytokine production from RAW
264.7 cells. First, an antibody filter array was used to sur-
vey the effects of TMP on cytokine production. The array
we used (mouse inflammatory antibody array 1, RayBio-
tech, Norcross, GA) simultaneously detects 21 cytokines
and/or growth factors and 15 chemokines. The array also
contains antibodies for tissue inhibitor of metallopro-
tease-1 (TIMP-1) and -2 (TIMP-2) and for soluble TNF
receptors 1 (sTNF R1) and 2 (sTNF R2). Images of repre-
sentative arrays are shown in Fig. 3, while semi-quantita-
tive data derived from these arrays are shown in Fig. 4. As
shown in Figs. 3A and 4A, only the cytokine MIP-1γ (coor-
dinates L5 and L6) was detected at substantial levels in
supernatants from unstimulated RAW 264.7 cells. We also
found that treatment with TMP itself did not exert a strongJournal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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Inhibition of prostaglandin production by TMP Figure 1
Inhibition of prostaglandin production by TMP. RAW 264.7 cells were incubated with LPS and/or TMP for the indicated 
times and then PGE2 concentrations in culture supernatants were determined by ELISA (A). RAW 264.7 cells were incubated 
with LPS in the presence of increasing concentrations of TMP and PGE2 concentrations were determined by ELISA (B). RAW 
264.7 cells were left untreated (Media) or treated with LPS and/or TMP and the concentrations in culture supernatants of 
PGF2α (C) and 6-keto-PGF1α (D) were determined by ELISA. RAW 264.7 cells were left untreated (Media) or treated with 
PMA (10 ng/ml) (E) or influenza A virus PR/8/34 (5 pfu/cell) (F) in the presence or absence of TMP and PGE2 concentrations in 
culture supernatants were determined by ELISA. Unless otherwise indicated concentrations of LPS and TMP were 1 μg/ml and 
25 μM, respectively, and the incubation time was 16 h. Panels A and B show representative experiments while the other panels 
show the mean ± SEM from 3 experiments. All samples were assayed in duplicate and error bars are less than symbol size 
where not shown. TMP was added simultaneously in experiments with LPS or PMA while TMP was added 30 m after infection 
with influenza A. In panels C-F, asterisks indicate significant differences between treatments with inducing agents alone and 
inducing agents with TMP (p < 0.05, Student's t-test).Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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effect on this profile (Figs. 3B and 4B). Subtle changes,
both increases and decreases, were seen in the levels of
several cytokines and again only MIP-1γ was detected at
high levels.
As expected, we found that stimulation of RAW 264.7 cells
with 1 μg/ml LPS dramatically enhanced the production
of a number of cytokines and chemokines (Figs. 3C and
4C). For purposes of discussion we have divided these
into two groups. One group of cytokines and chemokines
was induced to high levels, with mean pixel densities
within 75% of the positive controls included with the
array kit. The coordinates on the array of these cytokines
and chemokines are enclosed by solid ellipses in Fig. 3.
Included in this group are RANTES (A7/8), TNF-α (G7/8),
IL-6 (H3/4), MCP-1 (H5/6), MIP-1α (K5/6), and G-CSF
(L1/2). A second set of cytokines, including; GM-CSF (A3/
4), IL-1α (C3/4), M-CSF (I5/6), and IL-12p40p70 (K3/4)
was induced to a lesser degree. The coordinates of these
cytokines are enclosed by dashed ellipses in Fig. 3. Mean
pixel densities for cytokines in this group were typically
between 20–25% above negative controls. Finally, we
found that LPS also triggered an increase in the produc-
tion of TIMP-1 (E7/8) and sTNF R2 (I7/8).
As shown in Figs. 3D and 4D, we found that TMP exerted
a range of effects on LPS-induced cytokine production.
Among the cytokines normally induced by LPS to high
levels; TMP produced two levels of suppression. Very
slight suppression was noted for two cytokines, IL-6
(11%) and MIP-1α (8%), while substantially higher levels
of suppression were noted for RANTES (29%), G-CSF
The effects of TMP on expression and activity of COX-2 Figure 2
The effects of TMP on expression and activity of COX-2. RAW 264.7 cells were labeled overnight with [3H]-arachi-
donic acid, washed, then either left untreated (Media), or treated with LPS (1 μg/ml) and/or TMP (25 μM) for 16 h (A). Super-
natants were collected and radioactivity determined by scintillation counting. RAW 264.7 cells were treated with LPS (1 μg/ml) 
alone or in combination with TMP (25 μM) and copy number of COX-2 mRNA determined by q-RT-PCR as described in the 
Materials and Methods (B). RAW 264.7 cells were treated with LPS (1 μg/ml) and/or TMP (25 μM), and the expression of 
COX-2 protein was examined by Western blot (C). TMP was added to purified placental ovine COX-2 protein and specific 
activity determined as described in the Materials and Methods (D).Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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The effects of TMP on cytokine production Figure 3
The effects of TMP on cytokine production. RAW 264.7 supernatants were collected and assayed for cytokine produc-
tion using the Mouse Cytokine Array I (RayBiotech, Norcross GA). Shown in this figure are scans of films developed from 
array filters following incubation with supernatants from either untreated control cells (A), or from cells following incubation 
with 25 μM TMP (B), 1 μg/ml LPS (C), or 25 μM TMP and 1 μg/ml LPS (D). All supernatants were collected following a 16 h 
incubation period. The cytokines, chemokines, growth factors, and inflammatory products detected by the array and their 
respective coordinates are: Eotaxin, H1/2; Eotaxin-2, I1/2, Fas Ligand, J1/2; Fractalkine, K1/2; GCSF, L1/2; GM-CSF, A3/4; IFN-
γ, B3/4; IL-1α, C3/4; Il-1β, D3/4; IL-2, E3/4; IL-3, F3/4; IL-4, G3/4; IL-6, H3/4; IL-9, I3/4; IL-10, J3/4; IL-12p40p70, K3/4; IL-12p70, 
L3/4; IL-13, A5/6; IL-17; B5/6; I-TAC, C5/6; KC, D5/6; Leptin, E5/6; LIX, F5/6; Lymphotactin, G5/6; MCP-1, H5/6; M-CSF, I5/6; 
MIG, J5/6; MIP-1α, K5/6; MIP-1γ, L5/6; RANTES, A7/8; SDF-1, B7/8; TCA-3, C7/8; TECK, D7/8; TIMP-1, E7/8; TIMP-2, F7/8; 
TNF-α, G7/8, sTNF R1, H7/8; sTNF R2, I7/8. Positive controls are located at positions A1, B1, C1, D1, K8, and L8. Negative 
controls are located at positions A2, B2, C2, and D2. Blanks are located at positions E1, E2, J7, J8, K7, and L7. Solid and dashed 
ellipses indicate the coordinates of cytokines and chemokines induced by LPS to high and low levels, respectively, as discussed 
in the text.Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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(36%), TNF-α (43%), and MCP-1 (58%). TMP also
exerted a range of effects on the cytokines produced at
lower levels. Production of GM-CSF was blocked com-
pletely, while slight suppression was noted for IL-1α
(16%). In contrast, secretion of M-CSF was increased to a
small degree (7%), and that of IL-12p40p70 was
increased substantially (141%). TMP also inhibited pro-
duction of TIMP-1 (36%) and sTNF R2 (30%).
Since antibody filter arrays are typically semi-quantitative,
we sought to confirm several of the effects we had noted
using specific cytokine ELISAs. As shown in Fig. 5A, sup-
pression of TNF-α production measured by ELISA (42%)
very closely matched the level of suppression observed on
the array (43%). The suppressive effects of TMP were also
very similar for MCP-1 production, when measured by
ELISA (Fig. 5B) (67%) or by the array (58%). On the other
hand, ELISA did not confirm the inhibition of RANTES
production (Fig. 5C) noted on the array. At present, the
reason for this discrepancy is unclear. Finally, we also
used ELISA to investigate the TMP-dependent increase in
IL-12p40p70. The increase in IL12p40p70 noted on the
array, in the absence of an increase in IL-12p70 (Figs. 3D
and 4D), suggests that TMP enhances the LPS-dependent
production of p40 monomers or homodimers. Alterna-
tively, it is also possible that this represents production of
IL-23 since p40 is also a component of IL-23. As shown in
Fig. 5D, an ELISA specific for IL-12p40 confirmed the
finding from the array. However, an ELISA specific for IL-
23 (n = 3, 10 pg/ml sensitivity) did not detect any of this
cytokine (data not shown). We conclude, therefore, that
these supernatants contain either monomers or
homodimers of p40.
TMP and its effects on cytokine mRNAs
Next, a series of experiments was performed to define the
mechanism by which cytokine production was inhibited
by TMP. Specifically, we used quantitative RT-PCR to
investigate the effects of TMP on production of cytokine
mRNA. As shown in Fig. 6, we found a strong correlation
between the effects of TMP on cytokine protein levels, as
measured by ELISA, and expression of cytokine mRNA.
Levels of TNF-α protein and mRNA were reduced by 42
and 40%, respectively; while levels of MCP-1 protein and
mRNA were reduced by 67 and 76%, respectively. Simi-
larly, neither RANTES mRNA (Fig. 6C) nor protein (Fig.
5C) levels were suppressed by TMP. In fact, we measured
a small increase in RANTES mRNA following treatment
with TMP and LPS (Fig. 6C).
The effect of TMP on production of PGE2, cytokines, and 
chemokines by peritoneal macrophages
To further substantiate the results of our experiments with
RAW 264.7 cells, a set of experiments was performed with
normal mouse macrophages. Resident peritoneal macro-
phages were harvested from C57BL6/J mice, then treated
with LPS and/or TMP in vitro, and cell supernatants were
examined for PGE2 and several cytokines. As shown in Fig.
7, the results of these experiments were highly similar to
those seen with RAW 264.7 cells. Levels of PGE2, TNF-α,
and MCP-1 produced by peritoneal macrophages were all
reduced by TMP to extents comparable to those seen in
experiments with the RAW 264.7 cell line. The exception
was the effect of TMP on the production of IL-12/23 p40.
TMP did not enhance IL-12/23 p40 production from LPS-
treated peritoneal macrophages as it did with LPS-treated
RAW 264.7 cells. Instead, levels of IL-12p40 were reduced
by approximately 60%.
The effect of TMP on production of cytokines in vivo
The finding that TMP inhibits production of TNF-α in vitro
raises the possibility that TMP may be useful in vivo in a
variety of inflammatory conditions. To test whether TMP
can inhibit the production of TNF-α in vivo we established
a transient endotoxemia model in C57BL6/J mice [39].
The mice were injected i.p. with 20 μg of LPS in the CPE
vehicle which caused the animals mild distress; the mice
huddled for 2–3 hours then returned to normal behavior.
We also found, as has been reported [39] that this dose of
LPS induced a transient increase in levels of serum TNF-α.
Serum levels of TNF-α peaked 2–3 h after injection with
LPS and returned to pre-injection levels by 1–2 h later
(data not shown). Two experiments were then performed
in which TMP was administered in the CPE vehicle fol-
lowed 1 h later by LPS. Serum was collected 3 h after the
LPS challenge and levels of TNF-α were determined by
ELISA. The results from the first of these experiments are
shown in Fig. 8A. As expected, we measured low levels of
TNF-α in the serum of mice that received PBS (19 ± 3 pg/
ml; mean ± SEM), CPE vehicle (60 ± 9 pg/ml), or TMP in
the CPE vehicle (49 ± 9). Much higher levels of TNF-α
were measured in mice first treated with the CPE vehicle
followed by LPS in PBS (657 ± 50); and, strikingly, we
found that TMP offset this increase by 41% (385 ± 19 pg/
ml).
We also examined these serum samples for PGE2 using an
ELISA kit that permits measurements of PGE2 in mouse
serum (#P9053-30, USBiological, Swampscott MA). The
results of these assays did not reveal any significant
changes in PGE2 concentration in any treatment group.
Levels of PGE2 varied from 2.5–5.0 ng/ml per mouse in
the PBS injected mice and remained in that range in
groups treated with TMP in CPE vehicle, CPE vehicle fol-
lowed by LPS, and TMP in CPE vehicle followed by LPS
(data not shown).
A second experiment was then performed to confirm the
effects of TMP on production of TNF-α. Overall, the results
were highly similar to those in the first experiment. WeJournal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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found low levels of TNF-α in the serum of mice treated
with PBS (21 ± 21 pg/ml), higher levels with LPS treatment
following installation of the CPE vehicle (430 ± 39) and
significant suppression with TMP (42%) (251 ± 52 pg/ml,
p < 0.05, Student's t-test). In this experiment, rather than
test for PGE2, we quantified levels of MCP-1. Our results
showed significant suppression (27%) by TMP of the LPS-
induced accumulation of MCP-1 in serum (Fig. 8B).
The effects of TMP on the growth of RAW 264.7 cells
Experiments summarizing the effects of TMP on the
growth of RAW 264.7 macrophage-like cells are shown in
Fig. 9. Using an assay that monitors DNA accumulation
(Cyquant) (Fig. 9A) we found that the growth of RAW
264.7 cells was inhibited at the higher concentrations of
TMP tested. For example, growth of RAW 264.7 cells was
inhibited by approximately 40% during a 24 h incubation
with 25 μM TMP. In contrast, as shown in Fig. 9B, we did
not detect any apoptosis at this concentration of TMP. The
lack of toxicity of TMP towards RAW 264.7 cells was con-
firmed in experiments where RAW 264.7 cells were tran-
siently exposed to 25 μM TMP. As shown in Fig. 9C, when
TMP is withdrawn following a 24 h exposure, the cells
quickly regain their normal rate of growth.
The effects of TMP on cytokine production Figure 4
The effects of TMP on cytokine production. Images of the arrays shown in Fig. 3 were analyzed using Photoshop (Adobe) 
and mean pixel intensity (x-axis) determined for each array position. Supernatants were collected from untreated control cells 
(A), or from cells following incubation with 25 μM TMP (B), 1 μg/ml LPS (C), or 25 μM TMP plus 1 μg/ml LPS (D). Mean inten-
sity values are plotted for the 24 products which were detected under one or more of the experimental conditions. SEM was 
less than 5% for each pair of array positions.Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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Discussion
Chronic activation or hyper-activation of the innate
immune system is the cause of many damaging inflamma-
tory and auto-immune pathological reactions. The secre-
tory products of activated macrophages are major
contributors to these reactions. Our goal in these studies
was to test whether TMP can inhibit the production of
macrophage derived pro-inflammatory cytokines and lip-
ids. Our impetus was twofold; to better understand the
mechanisms underlying the traditional anti-inflamma-
tory uses for L. tridentata, and to determine whether a safe,
potentially effective anti-cancer drug might have an alter-
native use. The results of our experiments showed that
TMP can indeed inhibit the production of several key
macrophage products. Production of prostaglandins was
suppressed as was the production of certain cytokines and
chemokines raising the possibility that it may indeed be
useful to treat inflammation. Clearly, further study will be
necessary to determine the extent to which naturally
occurring tetra-O-methyl NDGA contributes to the anti-
inflammatory activity found in extracts of L. tridentata.
Excess prostaglandin production has been linked to a vari-
ety of inflammatory responses and auto-immune patho-
logical reactions. PGE2, for example, has been linked to
production of amyloid-β peptides in Alzheimer's disease
[40], while both PGE2 and PGI2/prostacyclin have been
linked to joint destruction during rheumatoid arthritis
[41,42]. Our experiments revealed broad suppression of
prostaglandin production by TMP in vitro with levels of
PGE2, PGF2α, and PGI2/prostacyclin all being reduced.
These results are consistent with those of early studies
The effects of TMP on cytokine production measured by ELISA Figure 5
The effects of TMP on cytokine production measured by ELISA. RAW 264.7 cells were left untreated (Media), or 
treated with either 1 μg/ml LPS and/or 25 μM TMP for 16 h. Culture supernatants were then analyzed by ELISA for TNF-α (A), 
MCP-1 (B), RANTES (C), or IL-12/23 p40 (D). All samples were assayed in duplicate and values shown are means ± SEM from 
2–3 independent experiments. Asterisks indicate significant differences between treatments with LPS alone vs. LPS with TMP (p 
< 0.05, Student's t-test).Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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The effects of TMP on copy number of cytokine mRNA Figure 6
The effects of TMP on copy number of cytokine mRNA. RAW 264.7 cells were left untreated (Media), or treated with 
LPS (1 μg/ml) and/or TMP (25 μM). After 16 h, total RNA was extracted from the cell pellet and mRNA copy number deter-
mined by q-RT-PCR for TNF-α (A), MCP-1(B) and RANTES (C). Panels show means ± SEM of representative experiments 
with duplicate copy number determinations performed in each experiment. Asterisks indicate significant differences between 
treatments with LPS and LPS/TMP (p < 0.05, Student's t-test).Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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which showed that NDGA, the parent compound of TMP,
could suppress prostaglandin production by primary
murine macrophages [43,44]. Our results suggested that
TMP may indeed be useful clinically to treat a number of
disorders and, therefore, we investigated the mechanism
underlying this activity. Because prostaglandin produc-
tion was suppressed regardless of the inducing agent (LPS,
phorbol ester, or influenza virus), we reasoned that it was
unlikely that TMP was interfering with signals from spe-
cific receptors such as TLR-4 [35]. Therefore we focused
our investigation on common, downstream elements in
the prostaglandin pathway such as cPLA2 [35], and COX-
2 [36,37]. TMP did not inhibit the LPS-induced release of
[3H]-arachidonic acid, which suggested that it was not
affecting the activity of cPLA2, and therefore we focused
our efforts on COX-2. Our experiments revealed a number
of effects of TMP on COX-2, including; a 40% reduction
in COX-2 mRNA, a 20% reduction in COX-2 protein, and
inhibition of COX-2 enzymatic activity. The effects of
TMP on the expression of COX-2 mRNA were not entirely
surprising since the 5' flanking region of the COX-2 gene
has 3 Sp1 binding sites [45] and TMP is known to inhibit
Sp1 binding to DNA [24]. Exactly how TMP's effect on the
expression of COX-2 mRNA ultimately impacts prostag-
landin production is not clear. The decrease in COX-2
mRNA resulted in only a modest decrease in COX-2 pro-
tein making it unlikely that this effect of TMP is a major
determinant of its ability to suppress prostaglandin pro-
duction. Rather, it seems that a direct inhibitory effect of
TMP on COX-2 enzymatic activity is primarily responsible
for the suppression of prostaglandin synthesis. This result
was unexpected. Although NDGA, the parent compound
of TMP, is widely known as an inhibitor of lipoxygenases,
direct inhibition of COX-2 activity by NDGA appears not
to have been described. In addition, lipoxygenase inhibi-
tion by NDGA is thought to depend on its anti-oxidant
activity, but this is greatly reduced in TMP, which carries
methyl rather than hydroxyl groups. Clearly, more studies
need to be performed to examine the interaction between
COX-2 and TMP and elucidate the mechanism of inhibi-
tion.
Our results suggest that TMP is a potent, direct inhibitor
of COX-2 activity, and the magnitude of this effect may be
The effects of TMP on cytokine, chemokine and inflammatory lipid production by peritoneal macrophages Figure 7
The effects of TMP on cytokine, chemokine and inflammatory lipid production by peritoneal macrophages. 
Macrophages were collected from C57BL6/J mice and left either untreated (Media), or treated overnight with 1 μg/ml LPS and/
or 25 μM TMP. Levels of PGE2 (A), TNF-α (B), MCP-1 (C) and IL-12/23 p40 (D) in cell culture supernatants were subsequently 
determined by ELISA. Panels show means ± SEM from 2–3 experiments for each mediator. Asterisks indicate significant differ-
ences between treatments with LPS and LPS/TMP (p < 0.05, Student's t-test).Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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sufficient to fully account for the suppression of prostag-
landin production by TMP in LPS-stimulated cells. How-
ever, since the yield of the various prostaglandins tested
was not affected equally by a fixed concentration of TMP,
it is conceivable that TMP may also affect the activity of
one or more of the prostaglandin synthases downstream
from COX-2. Further research will be required to evaluate
this possibility.
In this study we also addressed the effects of TMP on the
LPS-induced production of cytokines and chemokines by
RAW 264.7 cells. The antibody array we used revealed
increases in the production of 10 cytokines or chemokines
following treatment with LPS. We also measured
increased levels of TIMP-1 and sTNF R2 in culture super-
natants. Among these molecules, TMP failed to suppress
production of the chemokine MIP-1α, or the cytokines IL-
6, IL-1α, and M-CSF. On the other hand, suppression was
noted for the chemokine MCP-1, and for the cytokines
TNF-α, G-CSF, and GM-CSF. We also noted suppression
of production of TIMP-1 and sTNF R2. In contrast to the
results obtained for COX-2, we found a strong correlation
between the levels of cytokine mRNAs and their respective
protein products. TMP suppressed the accumulation of
TNF-α and MCP-1 mRNA and protein to similar extents,
while it had no effect on the accumulation of RANTES
mRNA or protein. The suppression of cytokine mRNA
accumulation by TMP in LPS-stimulated cells may be
determined by its ability to inhibit binding of the Sp1
transcription factor to DNA. Experiments with monocytic
cell lines have shown that Sp1 binding sites are required
for the LPS-induced activation of the TNF-α promoter
[46], whereas they are completely dispensable for activa-
tion of the RANTES promoter [47]. Although a direct
effect of TMP on cytokine gene transcription could
account for the reduced accumulation of mRNAs, other,
post-transcriptional mechanisms cannot be excluded. For
example, TNF-α production can be regulated at the level
of mRNA stability [48], as well as by protease cleavage of
the TNF-α precursor [49], and either of these might be
affected by TMP. Interestingly, if TMP inhibited the
expression or activity of the TNF-α converting enzyme, it
would be expected to reduce the levels of both secreted
TNF-α [49] and sTNF R2 [50], as we observed in our
experiments. Additional investigation will be required to
fully elucidate the mechanisms by which TMP suppresses
the production of various cytokines including its potential
effects on other transcription factors linked to inflamma-
tion, such as NF-κB.
Overall, for testing the effects of TMP on cytokine produc-
tion, the RAW 264.7 cell line proved to be an excellent
model, although we did find one major difference in its
response to LPS compared to that of peritoneal macro-
phages. Treatment with TMP caused an increase in the
expression of IL-12/23 p40 in LPS-stimulated RAW 264.7
cells, but this effect was not seen with LPS-stimulated peri-
toneal macrophages. In peritoneal macrophages, we
observed a response that was consistent with the effects of
TMP on other cytokines; namely inhibition of expression.
Why the LPS-dependent expression of IL-12/23 p40 is
increased by TMP in RAW 264.7 cells is not clear. Appar-
The effects of TMP on serum levels of TNF-α and MCP-1 Figure 8
The effects of TMP on serum levels of TNF-α and MCP-1. C57BL6/J mice (5/treatment) were used in a transient endo-
toxemia model to test TMP's ability to inhibit cytokine and chemokine production in vivo. One group of mice was injected only 
with PBS while a second group received only TMP (1 mg) in the CPE vehicle. Serum was collected from these mice after 4 h. A 
third group received the CPE vehicle followed 1 h later by 20 μg of LPS while a fourth group received 1 mg of TMP in the CPE 
vehicle followed 1 hr later by 20 μg of LPS. Serum was collected from these mice 3 h after the LPS injection. Levels of TNF-α 
and MCP-1 were determined by ELISA. Panels show means ± SEM from representative experiments. Asterisks indicate signifi-
cant differences between treatments with CPE vehicle followed by LPS and TMP in CPE vehicle followed by LPS (p < 0.05, Stu-
dent's t-test). n.d. – not determined.Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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The effects of TMP on the growth and viability of RAW 264 Figure 9
The effects of TMP on the growth and viability of RAW 264.7 cells. TMP was added to RAW 264.7 cells in vitro and 
their growth monitored for 24 h using the CyQuant proliferation assay (A). The induction of apoptosis in RAW 264.7 cells fol-
lowing a 24 h exposure to TMP was measured using an assay for active caspase 3 (Cayman) (B). In panels A and B, M and D 
indicate media and DMSO controls. In panel B, + and – indicate the addition of positive and negative controls supplied by the 
manufacturer. In C, cells were plated in 24 well plates, allowed to adhere 24 h, then washed and incubated with either fresh 
medium or medium containing 25 μM TMP. After 24 h, the medium containing TMP was removed from one set of wells, 
replaced with fresh medium without TMP, and the cells were incubated for an additional 48 h. Cell counts were determined by 
hemocytometer. Values shown are means +/- SEM and all points were performed in triplicate.Journal of Inflammation 2009, 6:2 http://www.journal-inflammation.com/content/6/1/2
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ently, the pathway(s) that regulate the expression of IL-
12p40 are altered in RAW 264.7 cells so that TMP causes
an enhancing effect.
Our experiments also revealed that TMP inhibited the
growth of RAW 264.7 cells. Based on the ability of TMP to
inhibit the growth of certain tumor-derived cell lines, and
its effects on Sp1, its effect on the growth of RAW 264.7
cells was not surprising. We did not detect any apoptosis
and the growth inhibitory effect disappeared when the
TMP was withdrawn, indicating that TMP is not damaging
towards RAW 264.7 cells and is likely causing reversible,
cell cycle arrest. In the future it will be interesting to deter-
mine whether there is a link between the growth inhibi-
tory effects of TMP and the ability of TMP to inhibit
production of cytokines and inflammatory lipids in RAW
264.7 cells. However, since peritoneal macrophages do
not grow in vitro, we can conclude that growth inhibition
is not a prerequisite for TMP to exert its anti-inflammatory
effects.
Based on the ability of TMP to inhibit cytokine and lipid
mediator production in vitro, we tested whether TMP
could exert these effects in vivo. We used a mouse model
of endotoxemia in which a sublethal dose of LPS is
administered i.p.  resulting in transient increases in the
serum levels of several cytokines. Increased cytokine levels
are evident within one hour; continue to rise for 2–3 hrs,
then return to pretreatment levels 1–2 hrs later. The
response to LPS under these circumstances is complex and
cytokine production involves many cell types from differ-
ent organs and tissues. LPS is transported from the perito-
neum to the liver via the portal vein [51] where both
hepatocytes and Kupffer cells respond by producing TNF
and other cytokines [52]. Likewise, spleen, brain and
bone marrow cells also produce cytokines following i.p.
exposure to LPS [52-54]. Whether these cells are respond-
ing directly to the LPS or to the cascade of cytokines pro-
duced by the liver is not entirely clear. Pharmacokinetic
experiments in mice indicate that TMP also spreads rap-
idly through the body following i.p. administration. Park,
et al. [29] have shown that 4 hours after a single i.p. injec-
tion of TMP (2 mg) it can be readily detected in a variety
of tissues and organs (liver, adipose tissue, brain, etc.) at
μM concentrations comparable to those we utilized in
vitro. TMP-mediated suppression of cytokine production
in vivo may therefore be occurring at a variety of anatomi-
cal locations outside the peritoneal cavity and defining
these sites will be the focus of future investigations.
It has been over two decades since TNF-α was identified as
one of the major mediators of endotoxemia and cachexia
[55]. Since then, TNF has been linked to a number of
auto-immune and inflammatory disorders including;
rheumatoid arthritis, inflammatory bowel disease, and
psoriasis, to name a few (reviewed in [56]). Although
expensive and difficult to administer, TNF-α blockers such
as Infliximab, Etanercept, or Adalimumab have proven to
be clinically effective for the management of these disor-
ders [57]. The results of our experiments showed that TMP
can reduce levels of TNF-α in vivo. While it is clear that
many additional experiments remain to be performed,
our results raise the possibility that TMP may be useful for
treating inflammatory diseases that are mediated by TNF-
α. Furthermore, the use of TMP may be advantageous over
that of other TNF-α blockers because TMP also inhibits
the production of other cytokines and inflammatory lip-
ids. Elevated levels of MCP-1, for example, have been
linked to psoriasis [58], while production of PGE2 con-
tributes to rheumatoid arthritis [59]. In both of these dis-
eases TMP might prove more effective than drugs that
target only TNF-α.
In summary, we have examined the ability of TMP to
inhibit the secretion of cytokines, chemokines, and
inflammatory lipids from activated macrophages. Our
results show that TMP can inhibit production of both
prostaglandins and several key inflammatory cytokines
and chemokines. Therefore, TMP could potentially be
used as a treatment for a number of different inflamma-
tory disorders.
Conclusion
￿ TMP inhibited production of prostaglandins from LPS-
stimulated RAW 264.7 cells and from murine peritoneal
macrophages.
￿ The ability of TMP to inhibit prostaglandin production
was linked to effects on levels of COX-2 mRNA and pro-
tein and to inhibition of COX-2 enzymatic activity.
￿ TMP inhibited production of several key inflammatory
cytokines and chemokines by RAW 264.7 cells and
murine peritoneal macrophages.
￿ The ability of TMP to inhibit cytokine and chemokine
production was correlated with effects on levels of
cytokine and chemokine mRNA.
￿ TMP reduced levels of TNF-α and MCP-1 in the serum of
mice challenged i.p. with a sublethal dosage of LPS.
￿ The ability of TMP to inhibit production of both protein
and lipid mediators of inflammation suggests that it may
have broad clinical application for the treatment of
inflammatory and autoimmune disorders.
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